2024年6月28日 · ESTEVE ACQUIRES HRA PHARMA RARE DISEASES. This expands ESTEVE's portfolio of medications for rare and severe diseases with three products to treat Cushing's syndrome and adrenocortical carcinoma; and drives its intern...

In the 90 years since our founding, ESTEVE has become a leading healthcare company in Spain, and now an international pharmaceutical innovator and partner with a purposeful expansion approach worldwide.

ESTEVE has an ambitious vision to become an international biopharmaceutical leader in specialty therapeutics. In our home country of Spain, neuroscience has been an area of focus for us. We also offer treatments in other therapeutic areas: - Ophthalmology: we are working on treatments for eye diseases such as dry eye and glaucoma.

Esteve Química, S.A. c/Caracas, 17-19 08030 Barcelona Spain Industrial Sites Production Plant Celrà. Esteve Química, S.A. Carrer Ter nº 94 17460 Celrà - Girona Spain Production Plant Banyeres del Penedès. Esteve Química, S.A. Ctra. Del Vendrell a St. Jaume dels Domenys, km 5 43711 Banyeres del Penedès - Tarragona Spain

ESTEVE by the numbers (2023) €710 M net revenues . 8 million patients impact of our products and activities + 2,000 worldwide employees +90 years of expertise. 110 brands in our portfolio + 55 countries with direct & indirect presence. Our values. People matter.

All news related to Esteve, the company, its research and its products and services.

We recognize and reward innovative approaches and behaviors, and we respect the contribution of all employees. We are strongly committed to addressing patients' needs - our reason for being.

2024年4月25日 · ESTEVE will increase its rare and severe diseases portfolio with three medicines addressing Cushing's syndrome and Adrenocortical Carcinoma. This is a step forward in the company's vision of being an international specialty pharma company.

2024年5月16日 · ESTEVE presents the consolidated annual report from 2023, together with the strategy and initiatives to foster the purpose of improving people's lives. ESTEVE successfully consolidated growth with net revenues reaching €710 million, reflecting a notable 10% increase compared to 2022.

Extensive catalogue of own products in areas of specialized medicine, as well as over-the-counter products with leading brands.